FDA Approved: DAPTOMYCIN — Supplemental Application (Sagent Pharmaceuticals)

View source ↗

Summary

FDA notice of a supplemental application for Daptomycin submitted by Sagent Pharmaceuticals, with the submission status shown as AP.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Complicated Skin and Skin Structure Infections
• Infective Endocarditis
• Staphylococcus Aureus Bacteremia

Drugs mentioned

• Daptomycin (daptomycin)

Snippet

SUPPL AP for DAPTOMYCIN (DAPTOMYCIN)